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Abstract
Background: The human prostacyclin receptor (hIP) undergoes agonist-induced phosphorylation,
desensitisation and internalisation and may be recycled to the plasma membrane or targeted for
degradation by, as yet, unknown mechanism(s).
Results: Herein it was sought to investigate the turnover of the hIP under basal conditions and in
response to cicaprost stimulation. It was established that the hIP is subject to low-level basal
degradation but, following agonist stimulation, degradation is substantially enhanced. Inhibition of
the lysosomal pathway prevented basal and agonist-induced degradation of the mature species of
the hIP (46-66 kDa). Conversely, inhibition of the proteasomal pathway had no effect on levels of
the mature hIP but led to time-dependent accumulation of four newly synthesised immature
species (38-44 kDa). It was established that both the mature and immature species of the hIP may
be polyubiquitinated and this modification may be required for lysosomal sorting of the mature,
internalised receptors and for degradation of the immature receptors by the 26S proteasomes
through the ER-associated degradation (ERAD) process, respectively. Moreover, these data
substantially advance knowledge of the factors regulating processing and maturation of the hIP, a
complex receptor subject to multiple post-translational modifications including N-glycosylation,
phosphorylation, isoprenylation, palmitoylation, in addition to polyubiquitination, as determined
herein.
Conclusion: These findings indicate that the hIP is post-translationally modified by ubiquitination,
which targets the immature species to the 26S proteasomal degradation pathway and the mature
species to the lysosomal degradation pathway.
Background
The prostanoid prostacyclin plays a central role in hae-
mostasis, acting as a potent inhibitor of platelet activation
and as a dilator of various types of smooth muscle [1]. It
has been implicated as a mediator of inflammation [2]
and as an inhibitor of vascular smooth muscle cell (SMC)
proliferation in vitro [3-5]. Additionally, stable prostacyc-
lin analogs inhibit the proliferation of proximal and distal
human pulmonary artery SMCs and human airway SMCs,
thereby suggesting their utility in the treatment of such
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[6,7]. Reduced prostacyclin activity, primarily following
genetic ablation of the prostacyclin receptor (IP) in mice,
has also been linked to increased risk of thrombosis,
injury-induced restenosis and atherosclerosis [2,8,9].
Moreover, numerous non-synonymous, in addition to
synonymous, mutations have been identified within the
coding sequence of the human (h) IP leading to receptor
dysfunction which, through genetic linkage studies, have
been associated with certain critical vascular disorders
including venous thrombosis and intima hyperplasia
[10].
The IP, a member of the G-protein-coupled receptor
(GPCR) superfamily, primarily couples to activation of
Gαs/adenylyl cyclase (AC) but may also regulate other sec-
ondary effectors in a cell- and species-specific manner
including to Gq- activation of phospholipase Cβ [11-16].
Like many other GPCRs, the hIP undergoes N-linked gly-
cosylation, a modification important for its membrane
localisation, ligand-binding and intracellular signalling
[17,18]. Additionally, it is subject to at least two types of
post-translational lipid modification, namely palmitoyla-
tion at Cys308 and Cys311 [19] and farnesylation/isopre-
nylation at Cys383 [20] within its proximal and distal
carboxyl-terminal (C)-tail domain, respectively. Both
palmitoylation and isoprenylation are proposed to result
in the formation of a putative double loop structure
within its C-tail domain and are required for efficient
hIP:G-protein coupling and effector signalling [19,20].
Ligand-induced activation of a given GPCR may typically
result in receptor phosphorylation, desensitisation and/or
endocytosis leading to internalisation into intracellular
compartments or vesicles [21,22]. Internalised receptors
may, in turn, then be recycled to the plasma membrane
where they are available for another round(s) of signalling
or may be targeted for degradation [21,22]. In the case of
the hIP, considerable data has been generated regarding
the mechanisms responsible for its phosphorylation,
internalisation and recycling [17,23-28]. Recent studies
have established that Rab5a GTPase plays a critical role in
the agonist-induced internalisation of the hIP and that
Rab4a and Rab11a are involved in its fast and slow recy-
cling, respectively, to the plasma membrane [24,27].
However, despite these investigations, little is known
about the mechanism(s) regulating the turnover or degra-
dation of the hIP under either basal or agonist-induced
conditions.
The main systems employed by cells to degrade proteins
are the lysosomes and the 26S proteasomes [29]. Lyso-
somes are vesicular organelles containing a variety of pro-
teases that function in an acidic environment to disrupt
peptide bonds [30]. The 26S proteasomes, consisting of a
20S core proteolytic particle and a 19S regulatory particle,
generally degrade proteins that have been post-transla-
tionally modified by attachment of the polypeptide ubiq-
uitin to the ε-amino group of Lys residue(s) of the
substrate in an ATP-dependent manner [31,32]. It is now
apparent that a number of GPCRs can be ubiquitinated
[33-37]. Agonist-induced ubiquitination of GPCRs does
not appear to target them for degradation by the proteas-
omes, but is instead required for endocytic sorting of the
internalised receptors and, ultimately, may target them for
lysosomal degradation [38,39]. On the other hand, ago-
nist-independent ubiquitination of a small number of
GPCRs has been identified and is mainly associated with
targeting of newly synthesised, misfolded GPCRs in the
endoplasmic reticulum (ER) for degradation by the
cytosolic proteasomes, through a process referred to as
ER-associated degradation, or ERAD [40,41].
In this study, it was sought to investigate turnover of the
hIP under basal conditions and in response to stimulation
with its selective agonist cicaprost. Owing to the relatively
low level of endogenous hIP, even within prostacyclin-
responsive cells of the vasculature, a previously character-
ised clonal HEK.hIP cell line which stably over-expresses
hemagglutinin (HA)-epitope tagged forms of the hIP was
used to facilitate these studies [42]. Our data establish that
the hIP is subject to low levels of degradation under basal
conditions but that upon agonist stimulation, its degrada-
tion is substantially enhanced. Inhibition of the lyso-
somal pathway prevented basal and agonist-induced
degradation of the mature hIP (46-66 kDa). Conversely,
while inhibition of the proteasomal degradation pathway
had no effect on the level of the mature hIP, it led to a
time-dependent accumulation of four newly synthesised
immature species of the hIP. Data presented herein also
suggest that both the mature and immature species of the
hIP may be polyubiquitinated and that this modification
may be required for lysosomal sorting of mature, internal-
ised receptors and for degradation of misfolded immature
receptors by the 26S proteasomes, respectively.
Results and Discussion
Identification of the Species of the hIP Expressed in HEK 
293 Cells
The human prostacyclin receptor (hIP) is subject to a
number of post-translational modifications, including N-
linked glycosylation, palmitoylation and farnesylation,
amongst others [17-20]. Hence, prior to investigation of
turnover of the hIP, it was initially sought to clarify the
identity of the molecular species of the hIP expressed in
HEK.hIP cells, a clonal mammalian cell line which stably
over-expresses hemagglutinin (HA) epitope-tagged forms
of the hIP [42]. Consistent with previous reports [17,19],
the HA-tagged hIP appeared as a broad, heterogeneous
band with an apparent molecular weight (MW) rangingPage 2 of 23
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discrete band was detected at ~44 kDa, with a less abun-
dant species detected at ~42 kDa (Figure 1A, lane 2). None
of these proteins were detectable in the host HEK 293 cells
(Figure 1A, lane 1).
A variety of reagents were then used to clarify the glyco-
sylation status of the hIP. Following exposure to tuni-
camycin for 24 hr, the 46 - 66 kDa species of the hIP was
still present but the 44 and 42 kDa species of the hIP were
not detected (Figure 1A, lane 3). Similarly, treatment of
whole cell protein prepared from HEK.hIP cells with
endoglycosidase H (Endo H) had no effect on the 46 - 66
kDa species of the hIP, but the 44 and 42 kDa species were
not detected (Figure 1A, lane 4). Treatment with peptide
N-glycosidase F (PNGase F) led to the disappearance of
the 46 - 66 kDa as well as the 44 and 42 kDa species of the
hIP and yielded a major species at ~40 kDa and a less
abundant form at ~38 kDa (Figure 1B, lane 4; Inset: pro-
longed exposure). Taken together, these data suggest that
the broad 46 - 66 kDa immunoreactive band represents
the mature species of the hIP containing a variable
number of complex N-linked glycans, which can only be
deglycosylated with PNGase F. On the other hand, the
sensitivity of the 44 and 42 kDa bands to tunicamycin
and/or Endo H treatment suggests that these may repre-
sent newly synthesised, endoplasmic reticulum (ER)-
localised species of the hIP that are core glycosylated,
while the 40 and 38 kDa forms may represent newly syn-
thesised, non-glycosylated species or intermediates of the
hIP that have had their core glycosylation units removed.
The inability to detect the 44 and 42 kDa species of the
hIP following tunicamycin or Endo H treatment will be
addressed at a later point herein.
As stated, the hIP is subject to farnesylation/isoprenyla-
tion at Cys383 within an evolutionary conserved -'CAAX'
motif [20], an immediate post-translational modification
that involves subsequent proteolysis of the -AAX (-
S384LC386) residues and carboxy-methylation to generate a
farnesyl-Cys383-methyl ester at the C-terminus of the iso-
prenylated protein. The nett result of such post-transla-
tional modifications is to generate a modified hIP that
displays faster migration properties, such as on SDS-
PAGE, than that of the nascent, non-modified hIP. Thus,
to investigate whether any of the hIP species detected may
be farnesylated, HEK.hIP cells were preincubated with the
farnesyl transferase inhibitor (FTI) SCH66336 [43-45].
Following SCH66336 treatment, the hIP mainly resolved
as the broad 46 - 66 kDa and more discrete 44 kDa species
with a significant reduction in the intensity of the 42 kDa
species (Figure 1B, lane 3; Inset: prolonged exposure).
These data suggest that the 44 kDa species of the hIP rep-
resents a precursor protein that may be modified by far-
nesylation to generate the 42 kDa species. Furthermore,
when HEK.hIP cells were pretreated with SCH66336 prior
to deglycosylation with PNGase F, only the major ~40
kDa, but not the minor 38 kDa, species was detected (Fig-
ure 1B, lane 5). Therefore, this 40 kDa species may repre-
sent the non-glycosylated, non-farnesylated species of the
hIP, while the 38 kDa species, detected only in the
absence of SCH66336, may represent the non-glyco-
sylated, farnesylated species of the hIP. It was also notice-
able that the hIP was detected as higher order oligomeric
forms following PNGase F treatment (Figure 1B, lanes 4 &
5). While these oligomers were detected in the presence or
absence of SCH66336, there was a slight decrease in the
mobility of each species detected in the presence of
SCH66336, suggestive of a lack of farnesylation (Figure
1B, compare lanes 4 & 5). As it is only the fully deglyco-
sylated, PNGase F-treated hIP that forms oligomers, they
are most likely to be an artifact of the deglycosylation
process itself and hence, are unlikely to be of physiologic
or biologic relevance in the cellular setting.
Investigation of Turnover of the hIP
To examine the turnover of the hIP under basal condi-
tions, HEK.hIP cells were pretreated with cycloheximide
(CHX) for 0 - 12 hr to prevent de novo receptor synthesis
where vehicle (0.001% DMSO)-treated cells served as
controls. In all cases, hIP expression levels were analysed
by western blot analyses, quantified by densitometry and
uniform protein loading was further verified by immuno-
blotting for HDJ-2, a ubiquitously expressed molecular
chaperone protein (Figure 2A - 2D, lower panels). No sig-
nificant turnover of the 46 - 66 kDa or of the 44 or 42 kDa
species of the hIP was apparent over the 12 hr incubation
in vehicle-treated cells (Figure 2A). Noteworthy, in gen-
eral, the 42 kDa species of the hIP was poorly detected at
the shorter exposure times, but was clearly evident follow-
ing prolonged exposures of the immunoblots. In the pres-
ence of CHX, the 44 and 42 kDa species of the hIP were
not detected 3 hr post-treatment and remained absent
upon CHX treatment up to 12 hr (Figure 2B). The level of
the 46 - 66 kDa species of the hIP remained stable up to 6
hr following CHX treatment, but from ~9 - 12 hr post-
treatment there was a minor but significant reduction in
levels of this species compared to vehicle-treated cells
(Figure 2B). The CHX did not appear to be effective at
inhibiting protein synthesis beyond 9 hr treatment, such
that in the presence of CHX the expression of the hIP
appears to recover at 9 - 12 hr. Hence, consistent with pre-
vious data (Figure 1), these data suggest that the 44 and 42
kDa species represent newly synthesised species of the hIP
and, furthermore, that the 46 - 66 kDa species represents
the mature hIP, which resolved as a broad band character-
istic of its glycosylation pattern in HEK 293 cells [17,18].
Overall, these data suggest that the level of hIP expression
is stable under basal conditions, with receptor degrada-
tion being compensated for by de novo receptor synthesis.Page 3 of 23
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Identification of the molecular species of the hIP expressed in HEK.hIP cellsFigure 1
Identification of the molecular species of the hIP expressed in HEK.hIP cells. A, western blot analysis of whole cell 
protein (50 μg) from HEK 293 cells (lane 1) or HEK.hIP cells (lanes 2-4) incubated with vehicle (0.001% DMSO, lanes 1, 2 & 4) 
or tunicamycin (2 μg/ml, lane 3) for 24 hr. Whole cell protein (50 μg) was treated with endoglycosidase H (Endo H, 200 units/
50 μg protein; lane 4). B, HEK 293 cells (lane 1) or HEK.hIP cells (lanes 2-5) were incubated in the absence (-) or presence (+) 
of SCH66336 (5 nM) for 24 hr prior to harvesting. Where indicated, whole cell protein (50 μg) was treated with PNGase F 
(500 units/50 μg protein, lanes 4 & 5). A &B, reactions were stopped by the addition of SDS-sample Buffer and proteins were 
resolved by SDS-PAGE, electroblotted onto PVDF membrane and screened with the anti-HA (3F10) antibody. B, Inset, the 
region highlighted by the dashed-line box in B is shown following long-term chemiluminescence exposure. The arrows 
between the panel and inset highlight the apparent molecular weights (MW) of the core glycosylated, non-farnesylated (44 
kDa); core glycosylated, farnesylated (42 kDa); non-glycosylated, non-farnesylated (40 kDa); and non-glycosylated, farnesylated 
(38 kDa) species of the hIP, respectively. The variably glycosylated mature hIP has an apparent MW of ~46-66 kDa. The higher 
MW species detected in panel B, lanes 4 & 5 may represent dimeric (*) and oligomeric (**) forms of the hIP. The positions of 
the molecular size markers (kDa) are indicated to the left of the panels. Data are representative of three independent experi-
ments.
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protein synthesis inhibitor CHX revealed minor turnover/
degradation of the hIP under basal conditions from ~9 hr
post-treatment.
It was next sought to determine the effect of agonist stim-
ulation on the expression and turnover of the hIP. In the
presence of cicaprost alone, there was a significant
decrease in the level of the mature 46 - 66 kDa species of
the hIP, particularly 6 - 9 hr poststimulation, suggesting
increased agonist-induced turnover/degradation of the
hIP (Figure 2C). However, concurrent with this turnover
of the mature hIP, there was also a significant increase in
levels of the newly synthesised 44 and 42 kDa species
(Figure 2C). Levels of the mature hIP then returned to lev-
els seen in untreated cells 12 hr poststimulation (Figure
2C). These data suggest that treatment of HEK.hIP cells
with agonist for up to 9 hr resulted in significant turnover
of the mature hIP; however, levels of the mature hIP were
restored following 12 hr and more sustained (24 hr, data
not shown) agonist stimulation, most likely due to de novo
protein synthesis. The molecular basis of the increased
levels of the newly synthesized hIP in the presence of cic-
aprost is currently unknown and may reflect alterations at
the transcriptional or translational level, in mRNA or pro-
tein stability due to increases in cicaprost-induced signal-
ling. In addition, the possibility that cicaprost itself or,
more likely, a second-messenger of cicaprost signalling
might act as a pharmacologic chaperone also cannot be
excluded.
The effect of inhibition of de novo protein synthesis prior
to stimulation of HEK.hIP cells with agonist was next
investigated. When CHX-treated cells were stimulated
with cicaprost, the level of the mature hIP was reduced
over time, with maximum turnover of the hIP detected ~9
- 12 hr poststimulation (Figure 2D). CHX blocked the syn-
thesis of the 44 and 42 kDa species of the hIP (Figure 2D),
thereby preventing replenishment of the levels of the
mature hIP from de novo synthesis. Overall, these data sug-
gest that minor turnover/degradation of the hIP occurs
under basal conditions, but sustained agonist stimulation
results in more substantial turnover of the hIP.
Investigation of Turnover of the hIP in the Presence of 
Lysosomal Inhibition
The majority of cellular proteins are degraded through the
lysosomal or the 26S proteasomal systems [29]. There-
fore, it was initially sought to investigate the role of lyso-
somal inhibition on turnover of the hIP. To this end, the
effect of treatment of HEK.hIP cells with the lysosomal
inhibitors chloroquine (CLQ), a weak base that disrupts
the action of lysosomal proteases by altering the pH
within the lysosomes [29], and E64, an alternative lyso-
somal Cys protease inhibitor, was investigated. Levels of
the mature, 46 - 66 kDa species and of the 44 and 42 kDa
species of the hIP were not reduced but actually were
modestly, and significantly, increased following treat-
ment of HEK.hIP cells with CLQ or E64 for 0 - 12 hr (Fig-
ure 3A &3B). Basal turnover of the hIP was then
investigated in the presence of CLQ plus CHX. The 44 and
42 kDa species of the hIP were not detected 3 hr post-
treatment (Figure 3C), further confirming that these spe-
cies represent newly synthesised receptors. Moreover, no
degradation of the mature hIP was evident when cells
were treated with CLQ plus CHX for up to 12 hr (Figure
3C), thereby suggesting involvement of the lysosomes in
basal degradation of the mature hIP.
Thereafter, the effect of CLQ on agonist-induced turnover
of the hIP was examined. Pretreatment of HEK.hIP cells
with CLQ prior to stimulation with cicaprost blocked the
agonist-induced turnover and actually led to an increase
in levels of the mature, 46 - 66 kDa species of the hIP over
the duration of the time course (Figure 3D). Levels of the
44 and 42 kDa species also increased significantly over
time (Figure 3D), suggesting that cicaprost stimulation
increased synthesis of new receptors. Pretreatment of
HEK.hIP cells with CLQ plus CHX prior to cicaprost stim-
ulation resulted in the disappearance of the 44 and 42
kDa newly synthesised species of the hIP, while levels of
the mature hIP were stable, and in fact significantly
increased at the later treatment times (Figure 3E). Overall,
while the role of the lysosome on the turnover of the
mature hIP appears to be quite low, this is reflective of the
fact that its rate of turnover is also low. However, data
obtained from studies employing the lysosomal inhibitor
CLQ do indeed suggest that both basal- and agonist-
induced degradation of the mature, 46 - 66 kDa species of
the hIP may occur in lysosomes, as pretreatment of
HEK.hIP cells with CLQ in the presence of CHX and/or
cicaprost prevented degradation of the 46 - 66 kDa species
of the hIP. Such turnover of the mature hIP by the lyso-
somal degradative pathway may be relatively slow and,
therefore, may be required to maintain a balance between
de novo protein synthesis and degradation.
Investigation of Turnover of the hIP in the Presence of 
Proteasomal Inhibition
It was next sought to investigate the effect of inhibition of
the proteasomal degradation pathway on turnover of the
hIP. Initially, the selective proteasomal inhibitor MG132,
a peptide aldehyde which reversibly inhibits the chymot-
rypsin-like active site of the proteasomes, was employed
[46,47]. Treatment of HEK.hIP cells with MG132 for 0 -
12 hr had no effect on levels of the mature, 46 - 66 kDa
species of the hIP (Figure 4A). However, strikingly, protea-
somal inhibition led to the rapid and time-dependent
accumulation of the 44 and 42 kDa species of the hIP and
induced the appearance over time of two further lowerPage 5 of 23
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Investigation of basal and agonist-induced turnover of the hIPFigure 2
Investigation of basal and agonist-induced turnover of the hIP. HEK.hIP cells were incubated with (A) vehicle (0.001% 
DMSO), (B) cycloheximide (CHX, 20 μg/ml) or (C) cicaprost (1 μM) for 0-12 hr. Additionally, cells were (D) pretreated with 
CHX (20 μg/ml) for 30 min prior to incubation with cicaprost (1 μM) for 0-12 hr. Whole cell protein (50 μg) was resolved by 
SDS-PAGE, electroblotted onto PVDF membrane and screened with the anti-HA (3F10) antibody (A - D, upper panels). Mem-
branes were stripped and reprobed with the anti-HDJ-2 antibody (A - D, lower panels). The positions of the molecular size 
markers (kDa) are indicated to the left of the panels. Data are representative of three to six independent experiments. The bar 
charts show the mean percentage increase or decrease in levels of the mature (46-66 kDa) species of the hIP ± S.E.M. (n = 3-
6) where the level of the mature hIP in untreated (0 hr) cells is assigned a value of 100%. **, p < 0.01 indicates that the mean 
percentage levels of the mature hIP was significantly reduced following the respective treatment(s) compared to those levels in 
untreated (0 hr) cells at that time point.
Journal of Molecular Signaling 2009, 4:7 http://www.jmolecularsignaling.com/content/4/1/7MW species of the hIP at ~40 and 38 kDa, respectively
(Figure 4A). These low MW species of the hIP that accu-
mulate upon MG132 treatment are shown more clearly in
the inset to Figure 4A. At this shorter exposure time, the
species that accumulate can be clearly distinguished as
four distinct species at ~44, 42, 40 and 38 kDa. The failure
to detect accumulation of the mature hIP in the presence
of MG132 suggests that the mature hIP may not be
degraded by the proteasomes.
MG132 is a highly selective agent that inhibits the activity
of the 26S proteasomes. However, it is also reported to
inhibit the activity of other cellular proteases, such as lys-
osomal Cys proteases or calpains [46]. Therefore, to inves-
tigate if the effects observed above in HEK.hIP cells using
MG132 were specific to the proteasomes, the effect of pre-
treatment of HEK.hIP cells with other selective proteas-
ome inhibitors was examined. To this end, epoxomicin, a
natural epoxyketone which is one of the most selective
inhibitors of the proteasome known, and lactacystin, a
non-peptide natural product that is structurally different
than MG132, were employed [46,48]. Similar to MG132,
the four low MW species of the hIP were detected when
HEK.hIP cells were treated with epoxomicin (Figure 4B)
or lactacystin (data not shown) for 12 hr. Furthermore,
pretreatment of HEK.hIP cells with the calpain inhibitor
PD150606 had no effect on the pattern of expression of
the hIP when compared to vehicle-treated cells (Figure
4C). Combined, these data suggest that the effects attrib-
uted to treatment of HEK.hIP cells with MG132, particu-
larly the accumulation of the low MW species of the hIP
at 44, 42, 40 and 38 kDa, were specific to its inhibitory
effect on the 26S proteasomes and not on other cellular
proteases, such as the calpains.
Thereafter, the effect of MG132 on basal and agonist-
induced turnover of the hIP was investigated. Treatment
of HEK.hIP cells with MG132 in the presence of CHX pre-
vented the expression of the low MW species of the hIP at
44, 42, 40 and 38 kDa within 3 hr (Figure 5A), again con-
firming that these all represent newly synthesised species.
However, inhibition of the proteasomal degradation
pathway with MG132 in the presence of CHX did not pre-
vent basal degradation of the mature hIP (Figure 5A) sim-
ilar to that observed in cells incubated with CHX alone
(Figure 2B), thereby suggesting that the 26S proteasomes
are not employed in basal degradation of the mature hIP.
Down-regulation of the mature hIP at 6 hr and more espe-
cially at 9 hr was apparent when HEK.hIP cells were stim-
ulated with cicaprost in the presence of MG132 (Figure
5B), thereby suggesting that proteasomes are not involved
in agonist-dependent down-regulation of the mature hIP.
However, intense accumulation of the four low MW spe-
cies of the hIP was seen from 6 hr poststimulation (Figure
5B). The increased rate of accumulation of these species
most likely occurred as a result of increased cicaprost-
induced de novo receptor synthesis. Consistent with this
hypothesis, pretreatment of HEK.hIP cells with MG132
plus CHX followed by incubation with cicaprost for 0 - 12
hr prevented the appearance of the four low MW species
of the hIP at 44, 42, 40 and 38 kDa within 3 hr (Figure
5C). Furthermore, while significant degradation of the
mature hIP was not evident until ~12 hr post-stimulation
(Figure 5C), there was no replenishment of levels of the
mature hIP due to the prevention of de novo receptor syn-
thesis with CHX. Collectively these data suggest that the
newly synthesised, low MW species of the hIP were
degraded by the 26S proteasomes. On the other hand,
degradation of the mature hIP does not appear to be
largely dependent on the proteasomes.
The effect of incubation of HEK.hIP cells with MG132 and
CLQ simultaneously was then examined. Accumulation
of the newly synthesised, low MW species of the hIP at 44,
42, 40 and 38 kDa was detected over time, while no deg-
radation of the mature, 46 - 66 kDa species of the hIP was
evident (Figure 5D). Synthesis and accumulation of the
low MW species of the hIP was increased when MG132-
and CLQ-pretreated HEK.hIP cells were stimulated with
cicaprost (Figure 5E). Taken together, these data suggest
that the hIP may be subject to two different modes of deg-
radation in HEK.hIP cells. Firstly, the mature, 46 - 66 kDa
species of the hIP may be degraded by a pathway employ-
ing the CLQ-sensitive lysosomes. Secondly, the newly syn-
thesised, low MW species of the hIP, which accumulate in
the presence of MG132 but not in the presence of CLQ,
appear to be degraded by the 26S proteasomes.
Clarification of the Identity of the Newly Synthesised 
Species of the hIP
To further investigate the nature of the species that accu-
mulate in the presence of MG132 and, specifically, to fur-
ther identify the farnesylated versus non-farnesylated
species of the hIP, HEK.hIP cells were preincubated with
the FTI SCH66336 for 24 hr prior to treatment with
MG132 or the vehicle (0.001% DMSO) for a further 0 - 12
hr. Analysis of total cellular protein from vehicle-treated
cells in the presence of SCH66336 indicated that the HA-
tagged hIP resolved as a broad 46 - 66 kDa band and as a
discrete 44 kDa band (Figure 6A), with no evidence found
for the 42 kDa species, even following prolonged expo-
sure to SCH66336 (data not shown). In the presence of
MG132 and SCH66336, there was a time-dependent accu-
mulation of the 44 and 40 kDa species of the hIP, but the
42 or 38 kDa species were not detected (Figure 6B). The
lane on the right of Figure 6B illustrates the accumulation
of all four immature species of the hIP in HEK.hIP cells
following treatment with MG132 (12 hr) in the absence
of SCH66336. Hence, inhibition of farnesylation pre-
vented the accumulation of the 42 and 38 kDa species ofPage 7 of 23
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Effect of lysosomal inhibition on basal and agonist-induced turnover of the hIPFigure 3
Effect of lysosomal inhibition on basal and agonist-induced turnover of the hIP. HEK.hIP cells were incubated with 
(A) chloroquine (CLQ, 100 μM), (B) E64 (20 μM) or (C) CLQ (100 μM) plus cycloheximide (CHX, 20 μg/ml) for 0 - 12 hr. 
Alternatively, cells were pretreated with either (D) CLQ for 30 min or (E) CLQ plus CHX for 30 min prior to incubation with 
cicaprost (1 μM) for 0-12 hr. A - E, whole cell protein (50 μg) was resolved by SDS-PAGE, electroblotted onto PVDF mem-
brane and screened with the anti-HA (3F10) antibody (upper panels). Membranes were stripped and reprobed with the anti-
HDJ-2 antibody (A - E, lower panels). The positions of the molecular size markers (kDa) are indicated to the left of A - E. 
Data are representative of three to five independent experiments. The bar charts show the mean percentage increase or 
decrease in levels of the mature (46-66 kDa) species of the hIP ± S.E.M. (n = 3 - 5) where the level of the mature hIP in 
untreated (0 hr) cells is assigned a value of 100%. *, p < 0.05, **, p < 0.01 and ***, p < 0.001 indicates that the mean percentage 
levels of the mature hIP was significantly increased following the respective treatment(s) compared to those levels in untreated 
(0 hr) cells at that time point.
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that these latter species can indeed be modified by the 15-
carbon farnesyl isoprenoid. Additionally, these data sug-
gest that the hIP can be glycosylated without being far-
nesylated.
It was next sought to clarify whether any of the low MW
species at 44, 42, 40 and 38 kDa that accumulate in the
presence of MG132 actually correspond to the species of
the hIP that are detected in the presence of SCH66336
and/or following PNGase F treatment. Pretreatment of
HEK.hIP cells with MG132 followed by deglycosylation
with PNGase F resulted in detection of the same two spe-
cies at 40 and 38 kDa as seen when cells were treated with
PNGase F alone (Figure 6C, compare lanes 4 & 5). Pre-
treatment of HEK.hIP cells with SCH66336 prior to degly-
cosylation resulted in detection of the 40 kDa species only
(Figure 6C, lane 6), which corresponds to the upper spe-
cies detected when cells were treated with PNGase F alone
or in combination with MG132 (Figure 6C, compare
lanes 4, 5 & 6). The region indicated by the white dashed-
line box in Figure 6C is also shown following short-term
chemiluminescence exposure in order to more clearly
highlight the presence or absence of these low MW species
following the various treatments (Figure 6C, Inset).
Treatment of HEK.hIP cells with tunicamycin or Endo H
resulted in loss of the 44 and 42 kDa species of the hIP
(see Figure 1A). To investigate whether this inability to
detect these species was due to their rapid degradation by
the 26S proteasomes, HEK.hIP cells were treated with
MG132 plus tunicamycin or with MG132 alone prior to
deglycosylation of total cellular protein with Endo H.
When tunicamycin-treated cells were incubated with
MG132, the 44 and 42 kDa species were not detected but
the 40 kDa and, to a lesser extent, the 38 kDa species was
detected (Figure 6D, lane 2). When total cell protein from
MG132-treated HEK.hIP cells was digested with Endo H,
the 44 and 42 kDa species were not detected but the 40
and 38 kDa species were detected, especially upon pro-
longed exposure (Figure 6D, lane 3). Therefore, these data
suggest that the tunicamycin- and Endo H-sensitive 44
and 42 kDa species of the hIP may normally be degraded
by the 26S proteasomes, thereby accounting for the ina-
bility to detect these species in Figure 1A (lanes 3 & 4).
Furthermore, these two lower MW species of the hIP
migrating at 40 and 38 kDa were similar to the two species
detected when HEK.hIP cells were deglycosylated with
PNGase F following MG132 treatment (Figure 6D, com-
pare lanes 3 & 4). Combined, these data clarify that the
four species that accumulate when HEK.hIP cells are incu-
bated in the presence of the proteasomal inhibitor
MG132 correspond to the core glycosylated, non-far-
nesylated (44 kDa); core glycosylated, farnesylated (42
kDa); non-glycosylated, non-farnesylated (40 kDa); and
non-glycosylated, farnesylated (38 kDa) species of the
hIP, respectively.
Investigation of the Subcellular Localisation of the Species 
of the hIP
Thereafter it was sought to examine the subcellular locali-
sation of the various species of the hIP following treat-
ment of HEK.hIP cells with MG132 for 12 hr, where
vehicle-treated cells served as controls. The HA-tagged hIP
resolved as three major bands at 46 - 66, 44 and 42 kDa,
respectively, which were detected in the total (T) and pel-
let (P100, representing crude membrane) fractions of vehi-
cle-treated cells (Figure 7, lanes 1 & 2). In the presence of
MG132, the 46 - 66 kDa species and the 44, 42, 40 and 38
kDa species were detected in the T and P100 fractions (Fig-
ure 7, lanes 4 & 5). However, trace levels of the 40 and 38
kDa receptor species were also present in the soluble,
supernatant/S100 fraction of MG132-treated (Figure 7,
lane 6) but not in the corresponding S100 fraction from
vehicle-treated cells (Figure 7, lane 3), even following pro-
longed exposure (data not shown). These data suggest
that these latter species represent newly synthesised, non-
glycosylated forms of the hIP or intermediates of the hIP
that have been deglycosylated and, in both cases, these
species may then be targeted for degradation by the
cytosolic proteasomes, presumably following their retro-
translocation from the ER in a process known as ER-asso-
ciated degradation (ERAD) [40,49].
Effect of Proteasomal Inhibition on Expression and 
Intracellular Signalling by the hIP
In view of the significant effects of MG132 on the expres-
sion of the hIP, its effect on the level of functional hIP
expression as monitored by assessment of radioligand-
binding and agonist-induced intracellular signalling of
the hIP was then examined. To begin with, the hIP was
typically expressed at 1.55 - 1.60 pmol/mg membrane
protein in HEK.hIP cells (Figure 8). Incubation with
MG132 for 3 - 12 hr significantly reduced expression of
the hIP relative to that of control, vehicle (0.001%
DMSO)-treated cells (Figure 8, p < 0.0001, ANOVA). It
was notable that cicaprost alone led to significant reduc-
tions in radioligand binding throughout the 0 - 12 hr
period (p < 0.0001, ANOVA; e.g. at 9 hr, 0.56 pmol/mg
membrane protein in HEK.hIP cells). The substantial
apparent loss in radioligand binding by the hIP, as
opposed to actual level of receptor protein expression, is
most likely due to the fact that the hIP is desensitized in
the presence of its own agonist cicaprost. Hence, in the
presence of cicaprost, specific radioligand binding may
not truly reflect actual protein expression.
Whilst the hIP primarily couples to Gαs/adenylyl cyclase
(AC) activation, it may also readily couple to Gαq/phos-
pholipase (PL) Cβ activation, leading to mobilisation ofPage 9 of 23
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Effect of proteasomal inhibition on the hIP expressed in HEK.hIP cellsFigure 4
Effect of proteasomal inhibition on the hIP expressed in HEK.hIP cells. A, HEK.hIP cells were incubated with MG132 
(10 μM) for 0-12 hr. Whole cell protein (50 μg) was resolved by SDS-PAGE, electroblotted onto PVDF membrane and 
screened with the anti-HA (3F10) antibody (upper panel). Inset, the region highlighted by the dashed-line box in A is shown 
following short-term chemiluminescence exposure where the arrows to the right of the Inset indicate the presence of the 
four predominant bands that accumulate in HEK.hIP cells following proteasomal inhibition with MG132. These bands corre-
spond to the core glycosylated, non-farnesylated (44 kDa); core glycosylated, farnesylated (42 kDa); non-glycosylated, non-far-
nesylated (40 kDa); and non-glycosylated, farnesylated (38 kDa) species of the hIP, respectively. Alternatively, HEK.hIP cells 
were incubated with (B) MG132 (10 μM) or epoxomicin (0.1 μM) for 12 hr or (C) PD150606 (20 μM) for 0, 6 or 12 hr. B &C, 
whole cell protein (50 μg) was resolved by SDS-PAGE, electroblotted onto PVDF membrane and screened with the anti-HA 
(3F10) antibody (upper panels). In all cases, membranes were stripped and reprobed with the anti-HDJ-2 antibody (A - C, 
lower panels). The positions of the molecular size markers (kDa) are indicated to the left of A - C. Data are representative of 
three to five independent experiments. The bar chart to the right of A shows the mean percentage increase or decrease in lev-
els of the mature (46-66 kDa) species of the hIP ± S.E.M. (n = 5) where the level of the mature hIP in untreated (0 hr) cells is 
assigned a value of 100%.
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effect of MG132 on agonist-induced [Ca2+]i mobilisation
was examined herein. Stimulation of HEK.hIP cells with
cicaprost led to a significant transient rise in [Ca2+]i mobi-
lisation (141.2 ± 5.76 nM, Figure 9; 0 hr). Pretreatment of
HEK.hIP cells with MG132 for 3 hr resulted in a 37%
reduction in levels of [Ca2+]i mobilised compared to
untreated cells (89.0 ± 4.11 nM, Figure 9; p < 0.01). Pro-
longed treatment of HEK.hIP cells with MG132 for 6 or 12
hr decreased levels of [Ca2+]i mobilisation by 35% and
50.2%, respectively, compared to untreated cells (91.8 ±
11.8 nM & 70.4 ± 4.48 nM, respectively, Figure 9; p <
0.01). As controls, pretreatment of these cells with vehicle
(0.001% DMSO) for up to 12 hr had no significant effect
on levels of [Ca2+]i mobilised compared to untreated cells
(145.0 ± 10.3 nM, Figure 9 while, in the absence of pre-
incubation, MG132 alone had no effect whatsoever on
cicaprost-induced [Ca2+]i mobilisation (154.67 nM ± 9.35
nM). Moreover, MG132 had no significant effect on lig-
and binding or on agonist-induced [Ca2+]i mobilisation
by the TPα isoform of the human thromboxane A2 recep-
tor, even following prolonged treatment (H. Reid, unpub-
lished data). Collectively, these data suggest that
proteasomal inhibition of HEK.hIP cells with MG132 spe-
cifically impairs the expression of functional hIP, as
observed by significant reductions in both radioligand
binding in crude membrane fractions and in agonist-
induced [Ca2+]i mobilisation. Moreover, collectively,
these data suggest that for efficient expression of func-
tional IP, an intact proteasomal system is required.
Investigation of Ubiquitination of the hIP
Proteins that are degraded by the 26S proteasomes are typ-
ically modified by attachment of ubiquitin moiety(ies)
prior to degradation [32]. Furthermore, many GPCRs may
be targeted for degradation by the lysosomes upon prior
ubiquitination of the internalised receptor [50,51]. Data
presented herein suggested that inhibition of the proteas-
omal degradation pathway in HEK.hIP cells with MG132
prevented the degradation of the newly synthesised spe-
cies of the hIP, while degradation of the mature, 46 - 66
kDa species of the hIP was prevented following inhibition
of the lysosomes. However, these assays were based solely
on western blot detection of the hIP and were not ana-
lysed for the detection of ubiquitination per se. Hence,
data generated thus far cannot exclude the possibility that
the hIP (immature and/or mature forms) may actually be
ubiquitinated. Therefore, it was next sought to investigate
whether ubiquitin-modified species of the hIP may be
detected in the absence or presence of proteasomal inhi-
bition.
To this end, an anti-ubiquitin (P4D1) antibody, which
recognises both mono- and polyubiquitinated proteins,
was employed to specifically screen for ubiquitinated spe-
cies of the hIP following immunoprecipitation of the HA-
tagged hIP with an anti-HA (Y-11) antibody. In all cases,
the immunoprecipitations were initially validated by
screening membranes with the anti-HA peroxidase-conju-
gated (3F10POD) antibody to detect the HA-tagged hIP
(Figure 10A, lower panel). In general, the resolution of the
hIP from immunoprecipitations was poorer than that
from direct protein analysis by SDS-PAGE, most likely due
to high residual detergent in the former accounting for
failure to resolve/detect all species of the hIP in the immu-
noprecipitates.
The anti-ubiquitin (P4D1) antibody revealed a diffuse
ladder or smear of bands ranging from ~72 - 220 kDa in
vehicle-treated HEK.hIP cells (Figure 10A, lane 5). Ubiq-
uitinated forms of the hIP were also detected following
stimulation of HEK.hIP cells with cicaprost (Figure 10A,
lane 6), albeit at slightly reduced levels than in vehicle-
treated cells (Figure 10A, compare lanes 5 & 6). The inten-
sity of ubiquitination of the hIP was greatly increased
when HEK.hIP cells were pretreated with MG132 either in
the absence or presence of cicaprost (Figure 10A, lanes 7
& 8, respectively). As a control, non-transfected HEK 293
cells were treated in a similar manner to the HEK.hIP cells;
however, no ubiquitinated species were detected in these
cells (Figure 10A, lanes 1 - 4). Collectively, these data sug-
gest that the hIP is subject to ubiquitination.
The immunoblot in Figure 10A is representative of the
pattern detected when cells were lysed under non-dena-
turing conditions prior to immunoprecipitation. How-
ever, because a range of proteins can associate with the
hIP, especially following its phosphorylation and inter-
nalisation, it was sought to establish whether the ubiqui-
tin observed was directly associated with the hIP. To this
end, HEK.hIP cells were lysed under denaturing condi-
tions prior to immunoprecipitation. No differences in the
patterns observed in Figure 10A, lanes 5 - 8, where the
cells were lysed under non-denaturing conditions, were
detected when HEK.hIP cells were lysed under denaturing
conditions (data not shown). These data suggest that the
ubiquitination was due to modification of the hIP itself
rather than due to modification of protein(s) that actually
bind or associate with the hIP.
The pattern of ubiquitination detected in the latter studies
was characteristic of the hIP being subject to polyubiqui-
tination rather than monoubiquitination. To verify this,
HEK.hIP cells were treated with vehicle (0.001% DMSO)
or MG132 and the HA-tagged hIP was immunoprecipi-
tated using an anti-HA (Y-11) antibody followed by
immunoblotting with an anti-ubiquitin (FK1) antibody,
which recognises polyubiquitinated proteins only. Low
levels of polyubiquitinated species were detected in
HEK.hIP cells in the absence of proteasomal inhibitionPage 11 of 23
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The effect of proteasomal and lysosomal inhibitors on basal and agonist-induced turnover of the hIPFigure 5
The effect of proteasomal and lysosomal inhibitors on basal and agonist-induced turnover of the hIP. HEK.hIP 
cells were incubated with (A) MG132 (10 μM) plus cycloheximide (CHX, 20 μg/ml), (B) MG132 (10 μM) for 30 min prior to 
incubation with cicaprost (1 μM), (C) MG132 (10 μM) plus CHX (20 μg/ml) for 30 min prior to incubation with cicaprost (1 
μM), (D) MG132 (10 μM) plus CLQ (100 μM) or (E) MG132 (10 μM) plus CLQ (100 μM) for 30 min prior to incubation with 
cicaprost (1 μM) for 0-12 hr. A - E, whole cell protein (50 μg) was resolved by SDS-PAGE, electroblotted onto PVDF mem-
brane and screened with the anti-HA (3F10) antibody (upper panels). In all cases, membranes were stripped and reprobed with 
the anti-HDJ-2 antibody (A - E, lower panels). The positions of the molecular size markers (kDa) are indicated to the left of A 
- E. Data are representative of three to five independent experiments. The bar charts show the mean percentage increase or 
decrease in levels of the mature (46-66 kDa) species of the hIP ± S.E.M. (n = 3-5) where the level of the mature hIP in 
untreated (0 hr) cells is assigned a value of 100%. *, p < 0.05 and **, p < 0.01 indicates that the mean percentage levels of the 
mature hIP was significantly increased or decreased following the respective treatment(s) compared to those levels in 
untreated (0 hr) cells at that time point.
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when cells were treated with MG132 (Figure 10B, lane 4).
As a control, no polyubiquitinated species were detected
in vehicle-treated HEK 293 cells (Figure 10B, lane 1),
while extremely low levels of polyubiquitinated species
were detected in MG132-treated non-transfected HEK 293
cells (Figure 10B, lane 2). Therefore, these data suggest
that the hIP was polyubiquitinated rather than monou-
biquitinated or multi-monoubiquitinated.
In further efforts to validate ubiquitination of the hIP,
HEK.hIP cells were cotransfected with or without a plas-
mid encoding 3xFlag-tagged Ubiquitin (3xFlagUb). Fol-
lowing cell lysis, the HA-tagged hIP was
immunoprecipitated using the anti-HA (Y-11) antibody
and, in all cases, immunoprecipitations were validated by
immunoblotting for the HA-tagged hIP (Figure 11A,
lower panels). Blots were then rescreened using a mono-
clonal anti-Flag M2 antibody specific for the Flag epitope.
No ubiquitinated species were detected in HEK.hIP cells
in the absence of cotransfection with 3xFlagUb (Figure
11A, upper panels, lane 4), thereby indicating the specifi-
city of the anti-Flag antibody. The characteristic smear of
bands representing polyubiquitinated species was evident
when HEK.hIP cells were transfected with 3xFlagUb (Fig-
ure 11A, upper panels, lane 3). Very low levels of ubiqui-
tinated species were detected when HEK 293 cells were
transfected with 3xFlagUb (Figure 11A, upper panels, lane
1); however, these were significantly lower than the levels
seen in HEK.hIP cells (Figure 11A, upper panels, compare
lanes 3 & 1).
Ubiquitination of transmembrane proteins located at the
ER membrane or the plasma membrane occurs on the
cytosolic or intracellular domains. It has been previously
reported that the hIP is internalised in a manner depend-
ent, at least in part, on the GTPase dynamin [25]. There-
fore, inhibition of hIP internalisation through co-
expression of a dominant negative dynaminK44A enhances
the level of hIP retained at the plasma membrane, thereby
increasing the possibility of detecting ubiquitinated hIP,
as has been reported for other ubiquitinated GPCRs
[37,52]. Hence, HEK.hIP cells were cotransfected with
3xFlagUb and dynaminK44A and the HA-tagged hIP was
immunoprecipitated using the anti-HA (Y-11) antibody
prior to immunoblotting versus the anti-Flag antibody.
Indeed, co-expression of dynaminK44A dramatically
increased the level of ubiquitinated species of the hIP
detected compared to levels in cells transfected with
3xFlagUb alone (Figure 11A, upper panel, compare lane 5
to lane 3). As a control, no Flag-tagged ubiquitinated spe-
cies were detected in the absence of cotransfection with
3xFlagUb or dynaminK44A (Figure 11A, upper panels, lane
6). Therefore, these data suggest that the mature hIP may
be polyubiquitinated.
Finally, HEK.hIP cells were then cotransfected with
3xFlagUb and treated with MG132 in the presence or
absence of cicaprost prior to immunoprecipitation of the
HA-tagged hIP. The immunoprecipitations were validated
by initially immunoblotting using the anti-HA 3F10POD
antibody (Figure 11B, lower panel). High levels of Flag-
tagged ubiquitinated species were observed in the absence
of agonist (Figure 11B, upper panel, lane 1), while ubiq-
uitinated species were also detected when cells were pre-
treated with cicaprost (Figure 11B, upper panel, lane 2).
As a control, HEK.hIP cells were cotransfected with
3xFlagUb and treated with cicaprost in the absence of
MG132 (see lane 4 in the additional panel to the right of
Figure 11B). While ubiquitinated species were detected in
the presence of cicaprost alone, the levels were slightly
lower than those seen when cells were treated with both
cicaprost and MG132 (Figure 11B, compare lane 2 to lane
4). These data indicate that inhibition of the proteasomal
degradation pathway with MG132 significantly increases
the level of ubiquitinated species detected in HEK.hIP
cells cotransfected with 3xFlagUb (compare Figure 11A,
lane 3 to Figure 11B, lane 1).
Taken together, as presented in Figure 12, our data sug-
gests a model in which the hIP may be degraded by two
alternative pathways. In the first pathway (B), it is pro-
posed that newly synthesised but misfolded species of the
hIP may be retrotranslocated from the ER to the cytosol,
most likely through the Sec61 channel [53]. Such retro-
translocated species may then be polyubiquitinated and
targeted to the 26S proteasomes through the ERAD system
[40,49]. The proteasome inhibitors MG132 or epox-
omicin, but not the calpain inhibitor PD150606, leads to
the accumulation of 4 predominant immature forms of
the hIP representing the core glycosylated, non-far-
nesylated; core glycosylated, farnesylated; non-glyco-
sylated, non-farnesylated; and non-glycosylated,
farnesylated species, respectively. In general, it is thought
that approximately 40% of newly synthesised wild-type
proteins fail to mature correctly in the ER and, thus, are
removed by ERAD [54,55]. Moreover, polyubiquitination
and proteasomal degradation of several misfolded GPCRs
has been established including the δ-opioid receptor [41],
rhodopsin [56,57], the thyrotropin-releasing hormone
receptor [58] and the calcium-sensing receptor [59]. The
critical importance of ERAD is demonstrated by the fact
that if the quality control system in the ER breaks down it
can lead to the accumulation of proteins into aggregates in
cells, resulting in such pathophysiologic conditions as
Alzheimer's disease [60]. In addition, herein, while the
proteasomes do not appear to be required for degradation
of the mature hIP, viable proteasomes were required to
maintain the level of functional receptor as indicated
from the radioligand-binding studies and assessment of
agonist-induced [Ca2+]i mobilization. A possible explana-Page 13 of 23
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Clarification of the molecular species of the hIP expressed in HEK.hIP cellsFigure 6
Clarification of the molecular species of the hIP expressed in HEK.hIP cells. A &B, HEK.hIP cells were treated with 
SCH66336 (5 nM) for 24 hr and then incubated with (A) vehicle (0.001% DMSO) or (B) MG132 (10 μM) for 0-12 hr prior to 
harvesting. As a control, HEK.hIP cells were treated with MG132 (10 μM) for 12 hr in the absence of SCH66336 (panel to the 
right of B). Whole cell protein (50 μg) was resolved by SDS-PAGE, electroblotted onto PVDF membrane and screened with 
the anti-HA (3F10) antibody. Membranes were then stripped and reprobed with the anti-HDJ-2 antibody (lower panels). C, 
HEK.hIP cells were incubated with vehicle (0.001% DMSO, lanes 1 & 4), MG132 (10 μM, lanes 2 & 5) or SCH66336 (5 nM, 
lanes 3 & 6) for 12 hr prior to harvesting. Where indicated, whole cell protein (50 μg) was treated with PNGase F (500 units/
50 μg protein; lanes 4-6). Inset, the region highlighted by the dashed line box in C is shown following short-term chemilumi-
nescence exposure. D, HEK.hIP cells were pretreated with MG132 (10 μM, lanes 1, 3 & 4) or 10 μM MG132 plus 2 μg/ml tuni-
camycin (lane 2) for 12 hr prior to harvesting. Thereafter, where indicated, whole cell protein (50 μg) was treated with 
endoglycosidase H (endo H, 200 units/50 μg protein; lane 3) or PNGase F (500 units/50 μg protein, lane 4), where both short- 
and long-term exposures are shown. Panels B - D, the respective arrows indicate the presence or absence of the core glyco-
sylated, non-farnesylated (44 kDa); core glycosylated, farnesylated (42 kDa); non-glycosylated, non-farnesylated (40 kDa); and 
non-glycosylated, farnesylated (38 kDa) species of the hIP detected following the various treatments. The positions of the 
molecular size markers (kDa) are indicated to the left of the panels. Data are representative of three independent experiments.
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dent in the presence of proteasomal inhibition may be
that misfolded or misassembled receptors that accumu-
late in the presence of MG132, and which would nor-
mally be taken out/degraded by ERAD, escape the ERAD
system and may thus be trafficked to the plasma mem-
brane leading to accumulation of non-functional recep-
tors.
In the second pathway of degradation (Figure 12C), it is
proposed that the mature hIP may be subject to basal or
agonist-induced degradation in the lysosomes whereby
the inhibitors chloroquine and E64 specifically impaired
turnover of the 46-66 kDa species of the hIP. However,
data obtained herein, particularly following co-expression
of 3xFlagUb and dynaminK44A and in response to cic-
aprost, provides evidence that some of the mature hIP at
least may also be polyubiquitinated and targeted to the
lysosomes for degradation (Figure 11). Whilst MG132 did
not appear to significantly affect the overall level of the
mature hIP (46-66 kDa), a number of independent
approaches herein confirmed that it may also be polyu-
biquitinated. Agonist-dependent ubiquitination of a
number of mammalian GPCRs has been established,
including the chemokine CXCR4 receptor [37,61], the V2
vasopressin receptor [33], the protease-activated receptor
2 [34] and the neurokinin 1 receptor [62]. Moreover, in
each case, inhibition of ubiquitination of these GPCRs
did not affect their internalisation into early endosomes,
but does prevent their subsequent lysosomal trafficking
and degradation. Whether ubiquitination of the mature
hIP is required for its internalisation from the plasma
membrane or whether ubiquitination of the mature hIP
occurs independently of its internalisation but is required
solely for its targeting to the lysosomal degradative system
remains to be determined. It is generally accepted that
ubiquitin is attached to substrates via covalent linkage of
the C-terminus of ubiquitin to the ε-amino group of Lys
residues of target proteins [29]. The hIP contains one Lys
in intracellular loop III (Lys218) and four Lys residues
(Lys297, Lys304, Lys342 and Lys376) in its C-tail that are
potential targets for ubiquitination. Studies are currently
underway to identify which Lys residue(s) of the hIP are
actually ubiquitinated.
As in many of the other aforementioned studies investi-
gating basal and agonist-induced turnover and ubiquiti-
nation of GPCRs, largely owing to the levels of
endogenous receptor expression the studies presented
herein for the hIP are also exclusively based on a heterol-
ogous expression system. Moreover, other experimental
approaches, such as mass spectrometry, may more accu-
rately or conclusively confirm the identity of the various
species of the hIP identified herein under the various con-
ditions. Hence, it is indeed plausible that some of the
observed effects herein, such as those in the presence of
MG132, may be accentuated due to impairment or inabil-
ity of the processing systems to deal with the level of hIP
expression in the recombinant HEK.hIP cell line. Not
withstanding this and the fact that the hIP is expressed at
significantly lower levels physiologically within the vascu-
lature, such as in platelets or VSMC [23,63], none the less
the data presented substantially advances knowledge of
the mechanisms of processing and maturation of the hIP,
a complex if not somewhat unique GPCR that undergoes
multiple post-translational modifications including phos-
phorylation, isoprenylation, palmitoylation, N-glycosyla-
tion, in addition to ubiquitination as determined herein.
Knowledge of the roles of ubiquitination of the hIP signif-
icantly enhances understanding of the mechanisms regu-
lating the function of the wild type hIP but may also, at
least in part, provide a possible explanation as to why
numerous nonsynonymous mutations, leading to dys-
functional hIP, have been increasingly recognized and are
associated with a range of vascular disorders including
venous thrombosis and intimal hyperplasia [10]. Moreo-
ver, knowledge of the factors determining the maturation
and processing of the hIP may provide a rationale for the
identification of potential therapeutic approaches to res-
cue hIP expression where normal physiologic function is
altered.
Conclusion
It was established that the hIP is subject to low-level basal
degradation but degradation is enhanced in response to
agonist. While the mature hIP may be polyubiquitinated
and targeted to the lysosomal pathway, the misfolded
immature species may be polyubiquitinated, retrotranslo-
cated from the endoplasmic reticulum and degraded by
the 26S proteasomes through the ERAD system. These
data substantially advance knowledge of the factors regu-
lating the processing and maturation of the hIP, a com-
plex GPCR subject to multiple post-translational
modifications including N-glycosylation, phosphoryla-
tion, isoprenylation, palmitoylation, in addition to poly-
ubiquitination as determined herein.
Methods
Materials
Cicaprost and SCH66336 were gifts from Bayer Schering
Pharma AG and Schering-Plough, Inc., respectively.
[3H]iloprost (15.3 Ci/mmol) was from Amersham Bio-
sciences. Cycloheximide (CHX), epoxomicin, E-64,
PD150606 and Fura2/AM were from Calbiochem. Pep-
tide-N-glycosidase F (PNGase F) and recombinant endog-
lycosidase H (Endo H) were obtained from New England
Biolabs. The chemiluminescence western blotting kit was
from Roche. Effectene® transfection reagent was from Qia-Page 15 of 23
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tin, N-ethyl maleimide (NEM), protein A-sepharose and
mouse monoclonal anti-FLAG M2 antibody (F 3165) were
obtained from Sigma-Aldrich. Hemagglutinin (HA)-
probe (Y-11, sc-805) rabbit polyclonal antibody, mouse
monoclonal anti-ubiquitin (P4D1, sc-8017) antibody and
horse radish peroxidase (HRP)-conjugated goat anti-rab-
bit IgG, goat anti-mouse IgG and goat anti-mouse IgM sec-
ondary antibodies were purchased from Santa Cruz
Biotechnology. Mouse monoclonal anti-polyubiquitin
(FK1, PW 8805) antibody was from Biomol International.
Mouse monoclonal anti-HDJ-2 antibody was from Neo-
markers. The oligonucleotides used in this study were syn-
thesised by Sigma-Genosys.
Plasmids
The plasmid pHM6:hIP has been previously described
[42]. The plasmids pCMV5:3xFlag Ubiquitin (3xFlagUb)
and pcDNA3:HA:DynaminK44A were kind gifts from Dr J.
Benovic, Thomas Jefferson University, PA, U.S.A.
Cell Culture and Stable Cell Lines
Human embryonic kidney (HEK) 293 cells, obtained
from the American Type Culture Collection, were cultured
in minimum essential medium (MEM), supplemented
with 10% foetal bovine serum (FBS). The HEK.hIP cell
line stably overexpressing a HA-tagged form of the hIP has
been previously described [42].
Cell Treatment, SDS-PAGE and Western Blotting
To investigate hIP turnover, HEK.hIP cells were seeded at
2 × 105 cells/well in 6-well plates and grown for 48 - 72 hr.
Thereafter, cells were treated with a range of compounds,
generally for 0 - 12 hr, as outlined in the Results section
and in the respective figure legends. Cells were harvested
in 1 × PBS, pH 7.4 containing protease inhibitors (0.5 mM
phenylmethylsulfonyl fluoride (PMSF); 2.0 mM 1, 10
phenanthroline; 10 μg/ml aprotinin; 1 mM benzamidine
hydrochloride; 1 μg/ml leupeptin). In all cases, protein
concentration was assayed using the Bradford assay [64].
Generally, 50 μg total cellular protein was resuspended in
SDS-sample Buffer (10% β-mercaptoethanol (v/v); 2%
SDS (w/v); 30% glycerol (v/v); 50 mM Tris-HCl, pH 6.8;
0.025% bromophenol blue (w/v)). Samples were then
boiled for 10 min prior to resolution by SDS-PAGE, on
10% polyacrylamide gels, followed by electroblotting
onto PVDF membrane. Blots were screened versus the
anti-HA (3F10; 1:1,000) antibody, followed by the sec-
ondary HRP-conjugated goat anti-rat IgG antibody
(1:5,000), and HA-tagged proteins were visualised using
the chemiluminescence detection system, as described by
the supplier. Membranes were then stripped and reprobed
using the anti-HDJ-2 antibody (1:4,000) to ensure equal
protein loading. All blots illustrated in the figures are rep-
resentative blots from 3 - 6 experiments (n = 3 - 6), where
the exposures presented are those that best represent the
experimental findings of all replicates. As relevant and
deemed necessary, two exposures (short and long) of cer-
tain data is presented for clarity. To quantify changes in
the levels of the mature hIP, regions of the anti-HA immu-
noblots corresponding to the 46-66 kDa region were cap-
tured using Adobe Photoshop (V6); band widths and
intensities were quantified and represented as levels of
HA-hIP expression under the various treatment condi-
tions and expressed as a percentage of the level of HA-hIP
expression under control/non-treated conditions.
Cell Fractionation
HEK.hIP cells were seeded at 2 × 106 cells/100-mm dish
and grown for 48 hr. Cells were then treated with MG132
Subcellular localisation of the hIP in the presence of MG132Figure 7
Subcellular localisation of the hIP in the presence of 
MG132. HEK.hIP cells were pretreated in the presence (+) 
or absence (-) of vehicle (0.001% DMSO, lanes 1-3) or 
MG132 (10 μM, lanes 4-6) for 12 hr. Aliquots of total (T; 50 
μg), membrane (P100; 37.5 μg) and soluble (S100; 25 μg) frac-
tions were resolved by SDS-PAGE, electroblotted onto 
PVDF membrane and screened with the anti-HA (3F10) anti-
body. The arrows at the right of the panel indicate the core 
glycosylated, non-farnesylated (44 kDa); core glycosylated, 
farnesylated (42 kDa); non-glycosylated, non-farnesylated (40 
kDa); and non-glycosylated, farnesylated (38 kDa) species of 
the hIP, respectively, that accumulate following the various 
treatments. The positions of the molecular size markers 
(kDa) are indicated to the left of the panel. Data are repre-
sentative of three independent experiments.Page 16 of 23
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12 hr prior to harvesting. An aliquot of total (T) cell pro-
tein was retained and the remaining cells were resus-
pended in Homogenisation Buffer (25 mM Tris/HCl, pH
7.5; 0.25 M sucrose; 10 mM MgCl2; 1 mM EDTA; 0.1 M
PMSF), homogenised on ice for 60 sec and then centri-
fuged at 100,000 × g for 60 min at 4°C. The soluble,
supernatant fraction (S100) was retained for analysis and
the pellet fraction (P100), representing crude membranes,
was washed in MES-KOH buffer (10 mM MES-KOH, pH
6.0; 10 mM MnCl2; 1 mM EDTA; 10 mM indomethacin)
prior to resuspension in 10 mM Tris-Cl, 1 mM EDTA, pH
8.0. Aliquots of the total, P100 and S100 fractions (50 μg/
lane) were then resolved by SDS-PAGE followed by
immunoblot analysis, as previously outlined.
Deglycosylation Reactions
HEK.hIP cells were seeded at 2 × 106cells/100-mm dish
and grown for 48 hr. Cells were then pretreated in the
presence (+) or absence (-) of SCH66336 (5 nM, 24 hr) or
MG132 (10 μM, 12 hr), as outlined in the respective figure
legends. Cells were harvested and aliquots (50 μg) of total
cell protein digested with PNGase F or Endo H, essentially
according to the suppliers' instructions. Briefly, cellular
protein was denatured in 1 × Glycoprotein Denaturing
Buffer (0.5% SDS, 40 mM dithiothreitol) at 100°C for 10
min. Thereafter, for digestions involving PNGase F, 1 × G7
Reaction Buffer (50 mM sodium phosphate, pH 7.5) and
1% NP-40 were added prior to addition of PNGase F (500
units/50 μg protein). For digestions involving Endo H, 1
× G5 Reaction Buffer (50 mM sodium citrate, pH 5.5) was
added prior to addition of 1 μl Endo H (200 units/50 μg
protein). All reactions were incubated at 37°C for 16 hr
and were terminated by addition of an equal volume of
SDS-sample Buffer and prepared for SDS-PAGE and
immunoblotting, as previously outlined herein.
Investigation of Ubiqutination of the hIP
HEK.hIP cells or, as control, HEK 293 cells were seeded at
2 × 106 cells/100-mm dish and grown for 72 hr. Cells were
treated with MG132 (10 μM), cicaprost (1 μM), MG132
(10 μM) for 30 min followed by stimulation with cic-
aprost (1 μM) or, as control, with vehicle (0.001%
DMSO) for 4 hr, as outlined in the respective figure leg-
ends. Cells were then lysed in Radio-immunoprecipita-
tion (RIP) Buffer (50 mM Tris-HCl, pH 8.0, 150 mM
sodium chloride, 5 mM EDTA, 1% NP-40 (v/v), 0.5%
sodium deoxycholate (w/v), 0.1% SDS (w/v)) supple-
mented with protease inhibitors (0.5 mM PMSF; 2.0 mM
1, 10 phenanthroline; 10 μg/ml aprotinin; 1 mM benza-
midine hydrochloride; 1 μg/ml leupeptin). Immunopre-
cipitations were carried out in the presence of N-ethyl
maleimide (NEM, 10 mM), an alkylating agent that inhib-
its the cellular deubiquitinating enzymes [65]. When per-
forming immunoprecipitations under denaturing
conditions, cells were lysed in RIP Buffer supplemented
with 1.0% SDS. Following 15 min incubation on ice, cells
were harvested and disrupted by sequentially passing
through hypodermic needles of decreasing bore size (18-,
21-, 23- and 26-gauge). Samples were centrifuged at
55,000 × g for 30 min at 4°C and HA-tagged receptors
from resulting supernatants (~600 μg) were immunopre-
cipitated with anti-HA antibody (Y-11, sc-805, 1:30 dilu-
tion) at 4°C for 1 hr. Protein A-Sepharose (50% slurry in
PBS; 50 μl) was then added and samples were incubated
at 4°C for a further 60 min. Immune complexes were col-
lected by centrifugation at 12,000 × g at 4°C for 5 min.
The supernatants were removed and the beads were
washed by resuspension in 600 μl RIP Buffer and then
incubated at 4°C for 10 min. Immune complexes were
collected by centrifugation at 12,000 × g at 4°C for 5 min
and this washing process was repeated a further three
times. The last traces of RIP Buffer were removed and pro-
teins were eluted from the beads with 30 μl of SDS-sample
Buffer. Generally, samples were then boiled for 10 min
prior to resolution by SDS-PAGE, on 8% polyacrylamide
gels, followed by electroblotting onto PVDF membrane.
Prior to immunoblotting, membranes were treated with
Denaturation Solution (62.5 mM Tris-HCl, pH 6.7, 100
mM β-mercaptoethanol, 2% SDS) for 30 min at 60°C.
While proteins subjected to SDS-PAGE are usually suffi-
ciently denatured, PVDF membranes were treated with
this solution to further denature the proteins prior to
Effect of MG132 on radioligand binding by the hIPFigure 8
Effect of MG132 on radioligand binding by the hIP. 
HEK.hIP cells were pretreated with DMSO (0.001%) or 
MG132 (10 μM) for 0-12 hr, with untreated cells serving as 
the reference. Cells were harvested and radioligand-binding 
assays were then performed on crude membrane (P100) frac-
tions in the presence of 4 nM [3H]iloprost at 30°C, as out-
lined in Experimental Procedures. The data are presented as 
the mean [3H]iloprost bound (pmol/mg protein ± S.E.M., n = 
4). For untreated cells (0 hr), the actual value for mean 
[3H]iloprost bound (pmol/mg protein ± S.E.M.) was 1.55 ± 
0.10 pmol/mg protein. ***, p < 0.0001 indicates that the 
mean [3H]iloprost bound (pmol/mg protein) ± S.E.M. was sig-
nificantly reduced in the presence of MG132 compared to 
DMSO at each time point.Page 17 of 23
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ble the detection of ubiquitinated proteins [37]. Mem-
branes were screened with anti-HA peroxidase-conjugated
antibody (3F10POD, 1:500) to detect HA-tagged recep-
tors. Subsequently, membranes were re-treated with
Denaturation Solution to remove bound antibody and
were reprobed with a mouse monoclonal anti-ubiquitin
(mono- and polyubiquitination) primary antibody
(P4D1, 1:5,000), followed by a secondary screening with
a HRP-conjugated goat anti-mouse IgG antibody
(1:10,000). Alternatively, membranes were reprobed with
a mouse monoclonal anti-ubiquitin (polyubiquitin) pri-
mary antibody (FK1, 1:5,000), followed by a secondary
screening with a HRP-conjugated goat anti-mouse IgM
antibody (1:10,000). Membranes were screened using the
chemiluminescence detection system, as described by the
supplier (Roche).
Additionally, ubiquitination of the wild-type hIP was
investigated following cotransfection of HEK.hIP cells
with pCMV5:3xFlag Ubiquitin (3xFlagUb) and/or
pcDNA3:HA:DynaminK44A. Specifically, HA-tagged
HEK.hIP or, as control, HEK 293 cells were seeded at a
density of 2 × 106 cells/100-mm dish. After 48 hr, cells
were transiently transfected with 1 μg total DNA, compris-
ing 270 ng pAdVA [66] plus 730 ng of the plasmid encod-
ing 3xFlagUb alone or 365 ng of 3xFlagUb plus 365 ng of
pcDNA3:HA:DynaminK44A or, as control, with an equiva-
lent amount of the respective empty vectors, pCMV5 or
pcDNA3, essentially as outlined in the respective figure
legends. Cells were then cultured for a further 48 hr.
Where indicated, HEK.hIP cells were treated with MG132
(10 μM) for 4 hr or were pretreated with MG132 (10 μM)
for 30 min prior to stimulation with cicaprost (1 μM) for
4 hr. Thereafter, cells were lysed in RIP buffer supple-
mented with protease inhibitors (0.5 mM PMSF; 2.0 mM
1, 10 phenanthroline; 10 μg/ml aprotinin; 1 mM benza-
midine hydrochloride; 1 μg/ml leupeptin) and NEM (10
mM) under non-denaturing or denaturing conditions, as
previously outlined. Supernatants were obtained and HA-
tagged receptors were immunoprecipitated by incubation
with anti-HA antibody (Y-11), as previously outlined.
Immunoprecipitates were resuspended in SDS-sample
Buffer, boiled for 10 min and resolved by SDS-PAGE, on
8% polyacrylamide gels, followed by electroblotting onto
PVDF membrane. Prior to immunoblotting, membranes
were treated with Denaturation Solution and were
screened with anti-HA peroxidase-conjugated antibody
(3F10POD, 1:500) to detect HA-tagged receptors. Subse-
quently, membranes were re-treated with Denaturation
Solution and reprobed with anti-Flag M2 mouse mono-
clonal antibody (1:5,000), followed by incubation with a
secondary HRP-conjugated goat anti-mouse IgG antibody
(1:10,000). Membranes were screened using the chemilu-
minescence detection system, as described by the supplier.
Radioligand-binding Assays
Radioligand-binding assays (RLBAs) of the hIP, over-
expressed in HEK.hIP cells, were carried out on crude cell
membranes (P100) using 4 nM [3H]iloprost essentially as
previously described [67]. To assess the effect of MG132
on the expression levels, HEK.hIP cells were pretreated
with MG132 (10 μM) for 3, 6, 9 or 12 hr prior to harvest-
ing. As a control, HEK.hIP cells were incubated with the
vehicle (0.001% DMSO) for the same times. Thereafter,
cells were washed three times with 1 × PBS to remove all
traces of MG132 and RLBAs were carried out as previously
described [67].
Measurement of Intracellular Ca2+ Mobilisation
Measurement of agonist-induced intracellular Ca2+
([Ca2+]i) mobilisation in Fura2/AM-preloaded cells was
carried out essentially as previously described [68]. To
assess the effect of MG132 on cicaprost-induced [Ca2+]i
mobilisation, HEK.hIP cells were pretreated with MG132
(10 μM) for 3, 6 or 12 hr. As controls, HEK.hIP cells were
left untreated or were pretreated with vehicle (0.001%
DMSO) for 12 hr. Thereafter, Fura2/AM-preloaded cells
Effect of MG132 on intracellular calcium ([Ca2+]i) mobilisa-tion by the hIPFigure 9
Effect of MG132 on intracellular calcium ([Ca2+]i) 
mobilisation by the hIP. HEK.hIP cells were pretreated 
with MG132 (10 μM) for 3 hr, 6 hr or 12 hr prior to harvest-
ing, where untreated (0 hr) or vehicle-treated (0.001% 
DMSO, 12 hr) cells served as controls. Cells were preloaded 
with Fura2/AM and stimulated with 1 μM cicaprost. In all 
cases, mean maximal changes in intracellular calcium mobi-
lised (Δ[Ca2+]i (nM) ± S.E.M.) were determined from at least 
four independent experiments. Actual mean Δ[Ca2+]i ± S.E.M. 
were: 0 hr, 141.2 ± 5.76 nM; vehicle, 12 hr, 145.0 ± 10.3 nM; 
MG132, 3 hr, 89.0 ± 4.11 nM; MG132, 6 hr, 91.8 ± 5.8 nM; 
and MG132, 12 hr, 70.4 ± 4.48 nM. Typically, actual baseline 
[Ca2+] levels in HEK.hIP cells were 10-15 nM. In all cases, 
mean maximal changes in intracellular calcium mobilised 
(Δ[Ca2+]i (nM) ± S.E.M.) were determined from at least four 
independent experiments. **, p < 0.01 indicates that the 
mean Δ[Ca2+]i was significantly reduced in the presence of 
MG132 compared to those levels in untreated cells at the 
specified time points (3, 6 & 12 hr).Page 18 of 23
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Immunodetection of ubiquitination of the hIPFigure 10
Immunodetection of ubiquitination of the hIP. A, HEK 293 (lanes 1-4) and HEK.hIP (hIP, lanes 5-8) cells were incubated 
in the presence (+) or absence (-) of vehicle (0.001% DMSO), cicaprost (1 μM) or MG132 (10 μM) for 4 hr. Additionally, cells 
were pretreated with MG132 (10 μM) for 30 min prior to incubation with cicaprost (1 μM) for 4 hr. B, HEK 293 (lanes 1 & 2) 
and HEK.hIP (hIP, lanes 3 & 4) cells were incubated in the presence (+) or absence (-) of MG132 (10 μM) for 4 hr. A &B, 
thereafter, cells were harvested, lysed in Radio-immunoprecipitation (RIP) Buffer and HA-tagged hIPs were immunoprecipi-
tated (IP) using the anti-HA antibody (IP: anti-HA (Y-11)), as described under Experimental Procedures. Immunoprecipitates 
were resolved by SDS-PAGE, followed by electroblotting to PVDF membrane. In each case, membranes were initially immuno-
blotted (IB) with the anti-HA peroxidase-conjugated antibody (IB: anti-HA (3F10POD), lower panels) to detect the HA-tagged 
hIP. A, membranes were rescreened with the anti-ubiquitin monoclonal antibody (IB: anti-Ub (P4D1), upper panel), which rec-
ognises both mono- and polyubiquitinated proteins. B, membranes were rescreened with the anti-ubiquitin monoclonal anti-
body (IB: anti-Ub (FK1), upper panel), which recognises polyubiquitinated proteins only. The positions of the molecular size 
markers (kDa) are indicated to the left of A &B. Data are representative of three independent experiments.
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Ubiquitination of the hIPFigure 11
Ubiquitination of the hIP. A, HEK 293 (lanes 1 & 2) and HEK.hIP (hIP, lanes 3-6) cells were transiently transfected with 
pCMV5:3xFlag Ubiquitin (3xFlagUb), pcDNA3:HADynaminK44A (DynaminK44A) or, as controls, with the empty vectors pCMV5 
or pcDNA3. B, HEK.hIP (hIP) cells were transiently transfected with pCMV5:3xFlag Ubiquitin (3xFlagUb) or, as control, with 
pCMV5 empty vector. Some 44 hr later, cells were treated with MG132 (10 μM) for 4 hr (lanes 1 & 3). Additionally, cells were 
pretreated with MG132 (10 μM) for 30 min prior to incubation with cicaprost (1 μM) for 4 hr (lane 2). As a control, cells were 
treated with cicaprost (1 μM) for 4 hr in the absence of MG132 (lane 4). A &B, thereafter, cells were harvested, lysed in 
Radio-immunoprecipitation (RIP) Buffer and HA-tagged hIPs were immunoprecipitated (IP) with the anti-HA antibody (IP: anti-
HA (Y-11)). Immunoprecipitates were resolved by SDS-PAGE, followed by electroblotting to PVDF membrane. A &B, mem-
branes were initially immunoblotted (IB) with the anti-HA peroxidase-conjugated antibody (IB: anti-HA (3F10POD), lower pan-
els) to detect the HA-tagged hIP and were rescreened with the anti-Flag monoclonal antibody (IB: anti-Flag (Flag M2), upper 
panel) to detect Flag-tagged ubiquitinated species. The positions of the molecular size markers (kDa) are indicated to the left of 
A &B. Data are representative of three independent experiments.
Journal of Molecular Signaling 2009, 4:7 http://www.jmolecularsignaling.com/content/4/1/7were stimulated with the IP agonist cicaprost (1 μM). Data
presented are representative of at least three independent
experiments and were calculated as mean changes in
intracellular Ca2+ mobilised (Δ[Ca2+]i ± S.E.M., nM; n = 4)
as a function of time (s) following ligand stimulation.
Data Analyses
Statistical analyses were carried out using the unpaired
Student's t-test or, where relevant and specifically indi-
cated in the text, using two-way ANOVA employing the
GraphPad Prism package. P-values of = 0.05 were consid-
ered to indicate a statistically significant difference.
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